重症COVID-19相关肺曲霉病与肺毛霉病诊治专家共识
重症COVID-19患者中CAPA发病率与病死率均高,CAPM虽相对少见但病情严重、易误诊延误致高病死率。中国医师协会呼吸医师分会危重症学组与中华医学会呼吸病学分会危重症学组组织专家,基于现有医学证据与临床实践制定本共识,经两轮讨论形成16条推荐意见,推荐强度分为推荐、建议、不推荐。内容涵盖胸部影像与支气管镜应用、微生物检查选择、诊断标准、抗真菌治疗时机与药物、疗程与疗效评估、抗炎治疗调整、基础病处理及手术指征。
要点
- 疑似CAPA或CAPM应尽早行支气管镜及BALF采集送微生物检查;CAPA诊断不能仅凭胸部CT阳性征象。
- 可能CAPA推荐尽早启动经验性抗曲霉治疗并同时获取微生物学证据;重症COVID-19尤其有CAPA危险因素者可建议两性霉素B或其脂质体预防。
- CAPA初始治疗推荐伏立康唑或艾沙康唑;CAPM初始治疗建议两性霉素B脂质体,肾功能不全或不耐受/不可及时可考虑艾沙康唑或泊沙康唑。
- CAPA疗程推荐至少6~12周;CAPM建议总疗程至少3~6个月,静脉治疗4~6周后根据疗效考虑序贯治疗。
- 重症COVID-19合并可能或很可能丝状真菌感染,建议停用或适当减少抗炎治疗,不建议在糖皮质激素基础上联用巴瑞替尼和/或托珠单抗。
适用人群与场景
- 重症COVID-19患者,尤其存在CAPA危险因素者。
- 临床疑诊(possible)或很可能(probable)CAPA或CAPM的危重症患者。
诊断标准与关键阈值
- CAPA诊断推荐采用修订版ECMM/ISHAM共识声明作为诊断标准。
- CAPM诊断推荐采用Delphi共识声明作为诊断标准。
处置流程与药物剂量
- 疑似CAPA或CAPM:推荐行胸部CT而非胸部X线,为支气管镜获取微生物标本提供诊断证据和定位;仅凭胸部CT阳性征象不能诊断CAPA;很可能CAPM患者推荐胸部增强CT或肺动脉CT(CTPA)。
- 疑似CAPA或CAPM:推荐尽早行支气管镜并采集BALF送微生物检查。
- 很可能CAPA:推荐BALF行镜检、培养、GM试验及曲霉属PCR;可能CAPM:建议BALF真菌染色与培养;危重症患者及可能CAPM建议选择合适标本行分子生物学检测。
- 重症COVID-19尤其有CAPA危险因素者:建议两性霉素B或其脂质体预防治疗CAPA。
- 可能CAPA:推荐尽早开始经验性抗曲霉治疗,同时获取曲霉病微生物学证据。
- 重症COVID-19患者:不推荐预防治疗CAPM。
- 可能CAPM:推荐早期启动经验性治疗,同时获取微生物学证据。
- CAPA初始治疗:推荐伏立康唑或艾沙康唑;CAPM初始治疗:建议两性霉素B脂质体;肾功能不全或两性霉素B脂质体不耐受/不可及时可考虑艾沙康唑或泊沙康唑。
红旗征与不能漏的情况
- 很可能CAPM需行胸部增强CT或CTPA评估。
- CAPA累及大血管、心包或胸壁,或反复/大咯血时考虑手术。
- CAPM广泛病变、快速进展或一般状况差者建议两性霉素B脂质体联合艾沙康唑或泊沙康唑。
研究设计与关键结果
- 中国医师协会呼吸医师分会危重症学组与中华医学会呼吸病学分会危重症学组组织专家组,基于现有医学证据与临床实践制定本共识,经两轮讨论最终确定16条推荐意见,推荐强度分为推荐、建议及不推荐。
证据类型、等级与局限
- 证据类型:专家共识;推荐强度标签为推荐、建议、不推荐。
- 局限:原文未报告局限性
对床旁实践的改变
- 对重症COVID-19疑诊CAPA者,应尽早经验性抗曲霉治疗并同时送微生物学证据,不应等待培养结果。
- CAPA初始治疗选择伏立康唑或艾沙康唑;CAPM初始治疗选择两性霉素B脂质体,肾功能不全时可考虑艾沙康唑或泊沙康唑。
- CAPA不推荐联合治疗作为初始方案,仅在挽救治疗时考虑三唑类或两性霉素B联合卡泊芬净或米卡芬净;不推荐两性霉素B联合三唑类。
- 重症COVID-19合并可能或很可能丝状真菌感染时,建议停用或适当减少抗炎治疗,不建议在糖皮质激素基础上联用巴瑞替尼和/或托珠单抗。
- CAPM确诊后推荐早期手术清除病灶,重症COVID-19患者手术为高风险操作,建议多学科团队讨论。
指南或共识出处
- 重症COVID-19相关肺曲霉病与肺毛霉病诊治专家共识,中国医师协会呼吸医师分会危重症学组与中华医学会呼吸病学分会危重症学组。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The incidence and mortality of COVID-19 associated pulmonary aspergillosis (CAPA) are high in critically ill patients. Although COVID-19 associated mucormycosis (CAPM) is relatively rare, its severity and often a delayed diagnosis or misdiagnosis lead to its high mortality. The diagnosis and treatment of CAPA and CAPM in critically ill patients are challenging. Early diagnosis and a standardized therapy are the two most important factors for a good outcome. Therefore, a working group of experts from Chinese Thoracic Society and Chinese Association of Chest Physicians Critical Care Group was organized to develop this consensus based on the current medical evidence and clinical practice, in order to improve the ability of clinical treatment for critically ill patients with CAPA and CAPM. The working group drafted a preliminary text based on the literature and clinical practice experience. Following two rounds of discussion, 16 final recommendations were made, with the recommendation strength divided into recommend, suggest and not recommend.-Utilization of chest images and bronchoscopy1. Chest CT, rather than chest X-ray, is recommended for possible CAPA or CAPM patients to provide diagnostic evidence and localization for bronchoscopy to obtain microbiological specimens. A diagnosis of CAPA could not be made on the basis of positive signs on chest CT alone. Chest contrast CT or pulmonary artery CT (CTPA) is recommended in patients with probable CAPM.2. In the case of possible CAPA or CAPM, it is recommended that bronchoscopy and BALF collection for microbiological examinations be pereformed as soon as possible.-The selection strategies of microbiological examinations3. Microscopic examination, culture, GM testing and PCR for aspergillus Spp. of BALF are recommended in patients with probable CAPA. Fungal staining and culture of BALF are suggested for possible CAPM. Selected appropriate specimens for molecular biological detection are suggested in critically ill patients and possible CAPM.-Diagnostic critieria4. The revised ECMM/ISHAM consensus statement is recommended as the diagnostic criteria for CAPA and the Delphi consensus statement is recommended as the diagnostic criteria for CAPM.-Appropriate time for antifungal therapy5. Prophylactic therapy of CAPA with amphotericin B or its liposomes is suggested for patients with severe COVID-19, especially those with risk factors for CAPA.6. It is recommended to start the empirical anti-Aspergillus therapy as soon as possible for possible CAPA, and obtain the microbiological evidence for aspergillosis at the same time.7. Prophylactic therapy for CAPM is not recommended for severe COVID-19 patients.8. Early initiation of empirical therapy for possible CAPM is recommended, and microbiological evidence should be obtained at the same time.-Clinical applications for antifungal agents9.Voriconazole or isavuconazole are recommended as initial treatment for CAPA. Amphotericin B liposomes are suggested as the initial treatment for CAPM. Isavuconazole or posaconazole may be an option in patients with renal insufficiency or amphotericin B liposome intolerance/unavailability.10. In CAPA patients with tracheobronchitis, antifungal drug inhalation is recommended in addition to systemic antifungal medication.11. Combination therapy is not recommended as initial therapy for CAPA, but may be used as a salvage therapy strategy. Triazole or amphotericin B in combination with caspofungin or micafungin is recommended; whereas amphotericin B in combination with triazole is not recommended. For CAPM patients with extensive lesions, rapid progression or poor general condition, a combination of amphotericin B liposome with isavuconazole or posaconazole is suggested.-Response assessment and treatment duration12. It is recommended that treatment response be assessed comprehensively according to the clinical symptoms/signs, imaging and microbiological examination of patients. CAPA can be evaluated in combination with the dynamic change in serum GM.13. The recommended treatment duration of CAPA is at least 6-12 weeks. A total course of at least 3-6 months is suggested for CAPM, and the sequential treatment should be considered according to the response to 4-6 weeks of intravenous therapy.-How to adjust the anti-inflammatory therapy14. In patients with severe COVID-19 combined with possible or probable filamentous fungal infection, it is suggested that of anti-inflammatory therapy be stopped or reduced appropriately, taking into account of the severity of the infection and inflammation of the disease course. The combination of baritinib and/or tozzizumab based on glucocorticoids is not suggested in these patients.-How to treat the underlying diseases15. In patients with diabetes, strict glycaemic control is suggested. In patients with long-term use of glucocorticoids and/or immunosuppressants, it is suggested to reduce the intensity of immunosuppression. Granulocyte colony-stimulating factor is suggested to use to improve the circulating granulocyte levels in patients with granulocyte deficiency due to various causes.-When an operation should be considered16. In patients with CAPA, surgery is not recommended unless large blood vessels, pericardium, or chest wall are involved, or the patient has recurrent or massive hemoptysis. For CAPM patients, early surgical removal of lesions after diagnosis is recommended. Surgery is a high-risk procedure in patients with severe COVID-19, and a multidisciplinary team discuss is suggested.
重症COVID-19相关肺曲霉病(CAPA)的发病率及病死率均较高。而新型冠状病毒感染相关肺毛霉病(CAPM)虽然相对少见,但疾病本身的严重性加之误诊及诊断延误也导致其病死率居高不下。目前,重症CAPA及CAPM的诊断及治疗均面临巨大挑战。如何早期诊断并规范治疗是救治成功的关键。因此,中国医师协会呼吸医师分会危重症学组与中华医学会呼吸病学分会危重症学组发起并组织相关领域专家,基于目前的循证医学证据及临床实践经验,撰写本共识,以期提高重症CAPA及CAPM患者的临床救治。工作组结合文献及临床实践经验,形成共识的初步文本。经两次讨论会,最终确定16条核心推荐意见并给出推荐强度,分为推荐、建议及不推荐。.
参考来源
- [Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary aspergillosis and mucormycosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38062689. doi:10.3760/cma.j.cn112147-20230823-00098
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。